Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/86941
Título: | Targeting cells with cathelicidin nanomedicines improves insulin function and pancreas regeneration in type 1 diabetic rats |
Autor(es): | Cristelo, C. Nunes, Rute Pinto, Soraia Marques, Joana Moreira Gama, F. M. Sarmento, Bruno |
Palavras-chave: | ß cell regeneration Cathelicidin Diabetes Nanomedicines Targeted delivery β cell regeneration |
Data: | 2023 |
Editora: | American Chemical Society |
Revista: | ACS Pharmacology & Translational Science |
Citação: | Cristelo, C., Nunes, R., Pinto, S., Marques, J. M., Gama, F. M., & Sarmento, B. (2023, October 3). Targeting β Cells with Cathelicidin Nanomedicines Improves Insulin Function and Pancreas Regeneration in Type 1 Diabetic Rats. ACS Pharmacology & Translational Science. American Chemical Society (ACS). http://doi.org/10.1021/acsptsci.3c00218 |
Resumo(s): | Type 1 diabetes (T1D) is an incurable condition with an increasing incidence worldwide, in which the hallmark is the autoimmune destruction of pancreatic insulin-producing β cells. Cathelicidin-based peptides have been shown to improve β cell function and neogenesis and may thus be relevant while developing T1D therapeutics. In this work, a cathelicidin-derived peptide, LLKKK18, was loaded in poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs), surface-functionalized with exenatide toward a GLP-1 receptor, aiming the β cell-targeted delivery of the peptide. The NPs present a mean size of around 100 nm and showed long-term stability, narrow size distribution, and negative ζ-potential (−10 mV). The LLKKK18 association efficiency and loading were 62 and 2.9%, respectively, presenting slow and sustained in vitro release under simulated physiologic fluids. Glucose-stimulated insulin release in the INS-1E cell line was observed in the presence of the peptide. In addition, NPs showed a strong association with β cells from isolated rat islets. After administration to diabetic rats, NPs induced a significant reduction of the hyperglycemic state, an improvement in the pancreatic insulin content, and glucose tolerance. Also remarkable, a considerable increase in the β cell mass in the pancreas was observed. Overall, this novel and versatile nanomedicine showed glucoregulatory ability and can pave the way for the development of a new generation of therapeutic approaches for T1D treatment. |
Tipo: | Artigo |
URI: | https://hdl.handle.net/1822/86941 |
DOI: | 10.1021/acsptsci.3c00218 |
ISSN: | 2575-9108 |
Versão da editora: | https://pubs.acs.org/doi/10.1021/acsptsci.3c00218 |
Arbitragem científica: | yes |
Acesso: | Acesso aberto |
Aparece nas coleções: | CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
document_56457_1.pdf | 11,54 MB | Adobe PDF | Ver/Abrir |